Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| fourth quarter 2023 product revenues exceeded prior year levels |
| As we make progress on our real-time aging studies, we remain confident in our ability to extend platelet kit shelf life |
| I think given the benefits of pathogen reduction and certainly the clinical benefits of IFC, we've been able to have more discretion [ph] on clinical utility and value than going in and competing against price |
| So, I think we're all encouraged about the growth prospects for this franchise |
| With the first two months of 2024 in the rear view mirror, we remain positive about the rest of the year ahead of us |
| This achievement marks the first time in the company's history of delivering positive adjusted EBITDA and we are committed to sustaining, if not improving on this measure for the full year 2024 as well |
| This momentum has continued through the first two months of 2024 and we feel confident in our ability to deliver compelling growth with our IFC business |
| We ended 2023 on several high notes posting double digit sequential growth for the fourth quarter, narrowing GAAP net loss attributable to Cerus, and importantly, delivering positive non-GAAP adjusted EBITDA for the first time |
| Per our 2024 product revenue guidance announcement earlier this year, we expect to post year-over-year double digit growth along with sustaining, if not improving bottom line results |
| As Obi indicated, we delivered strong sequential and year-over-year growth in the fourth quarter of 2023 |
| This growth was driven by our platelet franchise globally as well as encouraging progress within our U.S |
| Real world use of IFC continues to grow, and it has been encouraging to see the clinical enthusiasm for the offering |
| As we had predicted, the combination of strong growth in our top line coupled with stable margins and closely managed operating expenses allowed us to surpass non-GAAP adjusted EBITDA breakeven in the fourth quarter |
| Our platelet franchise delivered strong growth across the globe |
| We expect that these initiatives and results will translate into improvements in operating cash flows for 2024 and could potentially result in positive operating cash flows for the year |
| Q4 2023 margins improved over 2022 levels, primarily due to increased volumes and lower inventory costs compared to the prior year, offset by net foreign exchange rate impact on our reported margins |
| While we may have some fluctuations from quarter-to-quarter this year, we expect that with our product revenue guidance coupled with stable and perhaps slightly improving gross margins, continued leverage from the business and close management of operating expenses will support potential improvement on this measure for 2024 |
| We continue to see positive traction at our blood center customers and believe INTERCEPT remains the leading technology for platelet safety in the U.S |
| platelet franchise is poised for solid growth this calendar year |
| I feel really good about the pricing discipline that we've been able to execute on a global basis |
| Q4 2023 was a strong quarter for our U.S |
| IFC business will start to be a meaningful growth driver as well |
| As Vivek mentioned, we firmly believe in the prospects for IFC, evidenced by our commercial sales agreements with large national blood providers as well as the growing utilization and recognition of the product's benefit at an increased number of U.S |
| As you can see from the results, and which I'm happy to announce, we surpassed our goal of breakeven and in fact generated almost $5 million of positive non-GAAP adjusted EBITDA |
| On the bottom line reported net loss attributable to Cerus for the three months ended December 31, 2023 improved significantly when compared to the same period in the prior year |
| We continue to expect that the financial benefit from our restructuring will provide at least $10 million in annual life savings relative to expense levels at the time of the restructuring |
| During the fourth quarter of 2023, we surpassed the 16 million mark for cumulative kits sold for transusible INTERCEPT platelet and plasma doses |
| Furthermore, we saw growth in both existing accounts as well as a meaningful step up in new account activation notably, in our IFC business |
| And then may be Kevin for you, good to see the positive EBITDA in the quarter |
| On a going forward basis, we will provide you with more detail on the progress we are making with IFC and I am confident you will gain a greater appreciation for why we are excited about this business |
| Statement |
|---|
| Full year 2023 product revenues of $156.4 million were, as expected, down 4% year-over-year and in line with our guidance |
| Moving on, our fourth quarter operating expenses, which totaled $31.6 million, were over $10 million lower than the prior year period of the $41.8 million, a 24% decline |
| The conclusion of enrollment in our ReCePI study is the primary driver for the slight decline |
| So our top line guidance doesn't necessarily suggest linearity, so there is some chop to it |
| So just on the 2024 guide, it looks like it calls for a bounce back in platelets in the U.S |
Please consider a small donation if you think this website provides you with relevant information